Ociperlimab represents the important advance in addressing autoimmune disorders. Its experimental antibody drug inhibits neonatal-associated Fc receptor gamma-chain, a factor implicated in promoting destructive responses. Preliminary clinical findings demonstrate efficacy for diminishing manifestati